Pollen Counts At Claritin-D Study Sites Undermine 30-Minute Onset Claim
This article was originally published in The Tan Sheet
Executive Summary
The National Advertising Review Board decision shows that firms appealing recommendations by the National Advertising Division sometimes will receive different opinions from the appellate board of appointed experts, which considered appeals by both Bayer and Sanofi's Chattem from a NAD review.
You may also be interested in...
Bayer, Chattem Sneeze At NAD Decision On Claritin And Nasacort Comparison
NAD’s review of Bayer’s Claritin and Claritin-D ads upsets Bayer and challenger Chattem as both appeal the decision to the National Advertising Review Board. Bayer argues it supports the claim nothing “works faster” than Claritin-D, while Chattem says Bayer does not support claiming Claritin-D “starts to work on allergies in 30 minutes.”
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.